Omega Fund Management’s Lexeo Therapeutics LXEO Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2025
Q3
Sell
-1,184,636
Closed -$4.76M 14
2025
Q2
$4.76M Hold
1,184,636
3.08% 7
2025
Q1
$4.11M Hold
1,184,636
2.43% 7
2024
Q4
$7.79M Sell
1,184,636
-1,171,268
-50% -$9.23M 5.06% 5
2024
Q3
$21.3M Hold
2,355,904
13.31% 4
2024
Q2
$37.8M Hold
2,355,904
28% 2
2024
Q1
$36.9M Buy
2,355,904
+198,281
+9% +$3.1M 23.83% 2
2023
Q4
$29M Buy
+2,157,623
New +$26.8M 23.46% 1

Other funds holding LXEO

Omega Fund Management's LXEO Position: Q3 2025 in Review

Omega Fund Management sold out of Lexeo Therapeutics (LXEO) in Q3 2025, closing a stake of 1,184,636 shares — an estimated $4.76M sold.

Omega Fund Management first reported a position in LXEO in Q4 2023 and held it in 7 quarters. The position peaked at $37.8M in Q2 2024. 109 funds tracked by Wall St. Rank hold LXEO as of Q3 2025.

  • Omega Fund Management reported no remaining Lexeo Therapeutics position as of Q3 2025 after selling out during the quarter.
  • Omega Fund Management sold 1,184,636 Lexeo Therapeutics shares in Q3 2025, an estimated $4.76M.
  • Omega Fund Management first reported a position in Lexeo Therapeutics in Q4 2023 and held it in 7 quarters.
  • Omega Fund Management's Lexeo Therapeutics position peaked at $37.8M in Q2 2024.
  • 109 funds tracked by Wall St. Rank held Lexeo Therapeutics as of Q3 2025.

Based on Omega Fund Management's 13F filing for Q3 2025, filed 14 Nov 2025.